DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The "Oncolytic Virus Cancer Therapy- Pipeline Insights, 2018" report has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present scenario and growth prospects across Oncolytic Virus Cancer Therapy.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 65+ products with more than 25 companies involved. Some of the emerging products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio.

Products covered by Phase

Phase III, Phase II, Phase I IND Pre-clinical & Discovery Inactive

Overview of pipeline development activities for Oncolytic Virus Cancer Therapy

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Therapeutic segmentation of products for Oncolytic Virus Cancer Therapy The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

Scope

Provides an overview of therapeutic pipeline activity for Oncolytic Virus Cancer Therapy across the complete product development cycle including all clinical and non-clinical stages It comprises of detailed profiles of Oncolytic Virus Cancer Therapy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Oncolytic Virus Cancer Therapy

Key Topics Covered

Executive Summary Overview Introduction History of Oncolytic Virus Mechanism of Action Criteria of Selection on Oncolytic Virus for Cancer Therapy Strategies for Tumor Targeting Types of Cancer Treated Oncolytic Viruses vs Other Therapies Side effects of Oncolytic Viral Therapy Limitations of Oncolytic Viral Therapy Conclusion and Future Perspectives Pipeline Therapeutics (Active Products) Pipeline Therapeutics (Inactive Products) Comparative Analysis Late Stage Products (Phase III) Comparative Analysis Pexa-Vec: Transgene/SillaJen Product Description Research and Development Product Development Activities The list continues. Mid Stage Products (Phase II) Comparative Analysis Telomelsin: Oncolys Product Description Research and Development Product Development Activities The list continues.. Early Stage Products (Phase I & IND) Comparative Analysis Pre-clinical and Discovery Stage Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Inactive Products Comparative Analysis Appendix

Companies Featured

SillaJen Oryx PsiOxus Therapeutics Daiichi Sankyo Vyriad Genelux Takara Bio DNAtrix Merck Oncolytics Biotech Oncolys BioPharma Vrittu Biologics limited Transgene VCN Biosciences CZ Biomed Cell Genesys Lokon Pharma

For more information about this report visit https://www.researchandmarkets.com/research/4n9q94/oncolytic_virus?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005599/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 12:40 PM/DISC: 07/30/2018 12:41 PM

http://www.businesswire.com/news/home/20180730005599/en